HRP20161691T1 - Derivati ariletinila - Google Patents

Derivati ariletinila Download PDF

Info

Publication number
HRP20161691T1
HRP20161691T1 HRP20161691TT HRP20161691T HRP20161691T1 HR P20161691 T1 HRP20161691 T1 HR P20161691T1 HR P20161691T T HRP20161691T T HR P20161691TT HR P20161691 T HRP20161691 T HR P20161691T HR P20161691 T1 HRP20161691 T1 HR P20161691T1
Authority
HR
Croatia
Prior art keywords
compound
image
following formula
compounds
pharmaceutically acceptable
Prior art date
Application number
HRP20161691TT
Other languages
English (en)
Croatian (hr)
Inventor
Georg Jaeschke
Lothar Lindemann
Heniz Stadler
Eric Vieira
Original Assignee
F. Hoffmann - La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann - La Roche Ag filed Critical F. Hoffmann - La Roche Ag
Publication of HRP20161691T1 publication Critical patent/HRP20161691T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HRP20161691TT 2012-07-17 2013-07-12 Derivati ariletinila HRP20161691T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12176662 2012-07-17
PCT/EP2013/064747 WO2014012851A1 (fr) 2012-07-17 2013-07-12 Dérivés d'aryléthynyle
EP13735315.7A EP2875000B1 (fr) 2012-07-17 2013-07-12 Dérivés d'aryléthynyle

Publications (1)

Publication Number Publication Date
HRP20161691T1 true HRP20161691T1 (hr) 2017-02-24

Family

ID=48782352

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20161691TT HRP20161691T1 (hr) 2012-07-17 2013-07-12 Derivati ariletinila

Country Status (35)

Country Link
US (2) US20150133505A1 (fr)
EP (1) EP2875000B1 (fr)
JP (1) JP6089104B2 (fr)
KR (1) KR101631041B1 (fr)
CN (1) CN104364233B (fr)
AR (1) AR091764A1 (fr)
AU (1) AU2013292142B2 (fr)
BR (1) BR112014029015A2 (fr)
CA (1) CA2871389C (fr)
CL (1) CL2014003160A1 (fr)
CO (1) CO7111256A2 (fr)
CR (1) CR20140531A (fr)
CY (1) CY1118205T1 (fr)
DK (1) DK2875000T3 (fr)
EA (1) EA026593B1 (fr)
ES (1) ES2600133T3 (fr)
HR (1) HRP20161691T1 (fr)
HU (1) HUE030177T2 (fr)
IL (1) IL236362A (fr)
LT (1) LT2875000T (fr)
MA (1) MA20150280A2 (fr)
MX (1) MX358998B (fr)
MY (1) MY167810A (fr)
NZ (1) NZ701849A (fr)
PE (1) PE20150184A1 (fr)
PH (1) PH12014502695A1 (fr)
PL (1) PL2875000T3 (fr)
PT (1) PT2875000T (fr)
RS (1) RS55313B1 (fr)
SG (1) SG11201407050UA (fr)
SI (1) SI2875000T1 (fr)
TW (1) TWI473799B (fr)
UA (1) UA114911C2 (fr)
WO (1) WO2014012851A1 (fr)
ZA (1) ZA201408514B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA113223C2 (xx) * 2012-08-13 2016-12-26 Арилетинілпіримідини
EA026941B1 (ru) * 2012-10-18 2017-06-30 Ф. Хоффманн-Ля Рош Аг ПРОИЗВОДНЫЕ ЭТИНИЛА В КАЧЕСТВЕ МОДУЛЯТОРОВ АКТИВНОСТИ РЕЦЕПТОРА mGluR5
HRP20200638T1 (hr) 2015-06-03 2020-07-10 F. Hoffmann - La Roche Ag Derivati etinila
ES2733468T3 (es) 2015-07-15 2019-11-29 Hoffmann La Roche Derivados de etinilo como moduladores de los receptores metabotrópicos de glutamato
SI3484889T1 (sl) 2016-07-18 2020-11-30 F. Hoffmann-La Roche Ag Derivati etinila

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19546462A1 (de) * 1995-12-13 1997-06-19 Bayer Ag Diarylacetylenketone
PT1354875E (pt) 2003-05-19 2005-03-31 Servier Lab Novo processo de sintese do acido (2s, 3as, 7as)-per-hidroindole-2-carboxilico e dos seus esteres e aplicacao a sintese do perindopril
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
WO2006048771A1 (fr) 2004-11-04 2006-05-11 Addex Pharmaceuticals Sa Nouveaux derives de tetrazole utilises comme modulateurs allosteriques positifs des recepteurs de glutamate metabotropiques
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
NZ581817A (en) 2007-06-03 2012-05-25 Univ Vanderbilt Benzamide mglur5 positive allosteric modulators and methods of making and using same
CN101544892B (zh) * 2009-05-07 2012-10-03 石家庄诚志永华显示材料有限公司 一种合成二芳基乙炔类单体液晶的方法
US8420661B2 (en) * 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
KR101554803B1 (ko) * 2011-04-26 2015-09-21 에프. 호프만-라 로슈 아게 Mglur5의 양성 알로스테릭 조절체로서 에틴일 유도체

Also Published As

Publication number Publication date
US20160039787A1 (en) 2016-02-11
CY1118205T1 (el) 2017-06-28
CA2871389C (fr) 2020-08-25
CO7111256A2 (es) 2014-11-10
AU2013292142B2 (en) 2017-03-09
CR20140531A (es) 2015-01-12
ZA201408514B (en) 2015-12-23
UA114911C2 (uk) 2017-08-28
KR101631041B1 (ko) 2016-06-15
IL236362A (en) 2017-12-31
TW201408655A (zh) 2014-03-01
TWI473799B (zh) 2015-02-21
IL236362A0 (en) 2015-02-26
NZ701849A (en) 2016-07-29
EA026593B1 (ru) 2017-04-28
SG11201407050UA (en) 2014-11-27
PL2875000T3 (pl) 2017-03-31
EA201492274A1 (ru) 2015-05-29
HUE030177T2 (en) 2017-04-28
BR112014029015A2 (pt) 2017-06-27
PT2875000T (pt) 2016-11-03
MY167810A (en) 2018-09-26
CN104364233A (zh) 2015-02-18
PE20150184A1 (es) 2015-02-13
CA2871389A1 (fr) 2014-01-23
PH12014502695B1 (en) 2015-01-26
KR20150023766A (ko) 2015-03-05
JP2015527993A (ja) 2015-09-24
PH12014502695A1 (en) 2015-01-26
US20150133505A1 (en) 2015-05-14
SI2875000T1 (sl) 2017-01-31
MX358998B (es) 2018-09-12
AR091764A1 (es) 2015-02-25
DK2875000T3 (en) 2016-10-24
CN104364233B (zh) 2016-06-22
CL2014003160A1 (es) 2015-03-13
HK1202544A1 (zh) 2015-10-02
JP6089104B2 (ja) 2017-03-01
WO2014012851A1 (fr) 2014-01-23
MA20150280A2 (fr) 2015-08-31
RS55313B1 (sr) 2017-03-31
US9328090B2 (en) 2016-05-03
LT2875000T (lt) 2016-11-10
ES2600133T3 (es) 2017-02-07
AU2013292142A1 (en) 2014-11-06
EP2875000B1 (fr) 2016-09-21
EP2875000A1 (fr) 2015-05-27
MX2014014950A (es) 2015-03-09

Similar Documents

Publication Publication Date Title
ME02892B (fr) Composés chimiques
CA2826751C (fr) Procedes de synthese de quinoleines et compositions pharmaceutiques les incluant
PH12017501061B1 (en) 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infection
MD4490B1 (ro) Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin
EA201001683A1 (ru) Производные фенил- или пиридинилзамещенных индазолов
JP2015500843A5 (fr)
PH12014502524A1 (en) Carboxylic acid compounds
MX392440B (es) Inhibidores de tirosina quinasa de bazo (syk).
EA201200471A1 (ru) Простые эфирные производные бициклических гетероарилов
MD20140073A2 (en) New phosphate compounds, a process for their preparation and pharmaceutical compositions containing them
EA201592255A1 (ru) Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
EA201591804A1 (ru) Производные 2-((4-амино-3-(3-фтор-5-гидроксифенил)-1h-пиразоло[3,4-d]пиримидин-1-ил)метил)-3-(2-(трифторметил)бензил)хиназолин-4(3h)-она и их применение в качестве ингибиторов фосфоинозитид-3-киназы
AR086100A1 (es) Compuestos de cromenona y composiciones farmaceuticas que los contienen
EA201690072A1 (ru) Состав, содержащий гиполипидемическое средство
CA2920410C (fr) Derive thienopiperidine et son utilisation
NZ603108A (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
MX2016009581A (es) Derivados de 6-fenil- o 6-(piridin-3-il) indazol y metodos de uso.
MX2016009621A (es) Derivados de fur0-3-carboxamida y metodos de uso.
ME02351B (fr) Dérivés de 2-oxo-1-imidazolidinyl imidazothiadiazole
WO2014014794A3 (fr) Antagonistes des récepteurs aux minéralocorticoïdes
PH12015502717B1 (en) Anti-fibrogenic compounds, methods and uses thereof
WO2014160143A3 (fr) Composés d'isatine, compositions et procédés pour le traitement de maladies et de troubles dégénératifs
NZ701849A (en) Arylethynyl derivatives
UA117780C2 (uk) Похідні азаіндолоцтової кислоти та їх застосування як модуляторів рецепторів простагландину d2
JP2014508170A5 (fr)